Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History XNCR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics XNCR

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Xencor Inc

XNCR
Current price
8.42 USD +0.12 USD (+1.45%)
Last closed 8.30 USD
ISIN US98401F1057
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 599 258 112 USD
Yield for 12 month -53.69 %
1Y
3Y
5Y
10Y
15Y
XNCR
21.11.2021 - 28.11.2021

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California. Address: 465 North Halstead Street, Pasadena, CA, United States, 91107

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

28.20 USD

P/E Ratio

Dividend Yield

Financials XNCR

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures XNCR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+110 493 000 USD

Last Year

+168 338 000 USD

Current Quarter

+32 732 000 USD

Last Quarter

+70 018 000 USD

Current Year

+98 386 000 USD

Last Year

-85 260 000 USD

Current Quarter

+32 732 000 USD

Last Quarter

+70 018 000 USD
EBITDA -152 834 000 USD
Operating Margin TTM -131.93 %
Price to Earnings
Return On Assets TTM -11.42 %
PEG Ratio
Return On Equity TTM -34.05 %
Wall Street Target Price 28.20 USD
Revenue TTM 127 228 000 USD
Book Value 9.00 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 104.60 %
Dividend Yield
Gross Profit TTM -102 163 000 USD
Earnings per share -3.04 USD
Diluted Eps TTM -3.04 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -163.17 %

Stock Valuation XNCR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1.49
Price Sales TTM 4.71
Enterprise Value EBITDA -17.27
Price Book MRQ 0.92

Technical Indicators XNCR

For 52 Weeks

7.16 USD 27.24 USD
50 Day MA 8.88 USD
Shares Short Prior Month 8 676 123
200 Day MA 16.35 USD
Short Ratio 9.77
Shares Short 8 635 058
Short Percent 17.34 %